Evaluation of Patients With Liver Disease

Description

The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver. Patients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After the initial visit subjects will be requested to follow-up once a year at the outpatient department for a similar check-up. Additional tests may be requested throughout the study to provide information for other research studies and individual consent will be requested. These tests may include liver biopsies, skin biopsies, and / or specialized blood, plasma, and lymphocyte examinations. Subjects that qualify for medications presently being studied may be offered the opportunity to benefit from experimental therapy.

Conditions

Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver. Patients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After the initial visit subjects will be requested to follow-up once a year at the outpatient department for a similar check-up. Additional tests may be requested throughout the study to provide information for other research studies and individual consent will be requested. These tests may include liver biopsies, skin biopsies, and / or specialized blood, plasma, and lymphocyte examinations. Subjects that qualify for medications presently being studied may be offered the opportunity to benefit from experimental therapy.

Evaluation of Patients With Liver Disease

Evaluation of Patients With Liver Disease

Condition
Hepatitis D
Intervention / Treatment

-

Contacts and Locations

Bethesda

National Institutes of Health Clinical Center, Bethesda, Maryland, United States, 20892

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. \>=2 years of age.
  • 2. Meets one of the following:
  • 1. Suspected or evidence of acute or chronic liver disease on evaluation by a referring licensed independent practitioner (LIP), OR
  • 2. At risk for acute or chronic liver disease
  • 1. \>= 18 years of age.
  • 2. In good general health as evidenced by medical history
  • 1. History of significant medical illnesses that might interfere with prolonged follow up evaluation
  • 1. Any chronic medical condition, including (but not limited to) heart, kidney, or lung diseases
  • 2. Taking any regular medications or supplements (with the exception of regular multivitamins and/or oral contraceptives)
  • 3. Average alcohol consumption \> 1 drink/day in past 6 months, per self-report
  • 4. History of liver disease (with the exception of neonatal jaundice)
  • 5. History of severe illness, infection or major surgery in the past year
  • 6. History of cancer (with the exception of basal cell carcinoma resected \> 1 year prior to enrollment)
  • 7. BMI \< 18 or BMI \>25
  • 8. Hemoglobin \< 11 (women) or hemoglobin \< 12 (men)
  • 9. ALT \>35 (men) or ALT \>25 (women)
  • 10. Alkaline Phosphatase \>= 150
  • 11. Bilirubin \>2 g/dL
  • 12. HIV positive, Anti-HCV positive, HBsAg positive or Anti-HBc positive
  • 13. Pregnancy
  • 14. Inability to provide informed consent

Ages Eligible for Study

2 Years to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),

T. Jake Liang, M.D., PRINCIPAL_INVESTIGATOR, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Record Dates

N/A